MOPED
LIVE

Serial Number

97596410

Owner

Oncopia Therapeutics, Inc.

Attorney

Joyce M. Ferraro

Filing Date

Sep 19, 2022

Add to watchlist:

No watchlists yet
View on USPTO

MOPED Trademark

Serial Number: 97596410

MOPED is a trademark filed by Oncopia Therapeutics, Inc. on September 19, 2022. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Oncopia Therapeutics, Inc.

151 West 42nd Street, 15th Floor
New York, NY 10036

Entity Type: 03

Trademark Details

Filing Date

September 19, 2022

Registration Date

Not Registered

Published for Opposition

December 19, 2023

Goods & Services

Drug discovery services; DNA and protein screening for scientific research purposes; Platform as a service (PAAS) featuring computer software platforms for drug discovery, screenings, and providing pharmaceuticals; Scientific and technological services and research and design, namely, research and design in the field of drug discovery and DNA and protein screening; Scientific research and development in the field of analysis of technical data by computers; pharmaceutical drug discovery services; research and development in the pharmaceutical and biotechnology fields; drug discovery services and research and development in the pharmaceutical drug use field; design and development of pharmaceutical preparations and medicines; scientific research and development in the field of drug discovery; scientific research and development in the nature of conducting scientific and pharmaceutical research and data analysis to screen for and identify molecular interactions, compounds and detect toxicity; providing scientific, pharmaceutical and agrochemical database research services; scientific research and development in the nature of scientific and pharmaceutical artificial intelligence research services to identify molecules and compounds for drug discovery and chemical development; scientific research and development in the nature of bioinformatics services for using the combination of biology, computer science, information engineering, mathematics and statistics to analyze and interpret biological data; scientific research and development in the nature of computer assisted molecule design; scientific research and development in the nature of identification of biological targets, networks and pathways; biological research and analysis; pharmaceutical research and development services; computer aided diagnostic and DNA and protein screening services for scientific research purposes; scientific research and development in the nature of contract research services in support of scientific research and development of pharmaceutical preparations; Software as a service (SaaS) services featuring software to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; Software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; Software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement

Downloadable computer software for drug discovery, screenings, and providing pharmaceuticals; downloadable computer software for use to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry, clinical trial management and patient engagement

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 12, 2026 EXRA
SOU EXTENSION 4 GRANTED
Feb 12, 2026 EX4G
SOU EXTENSION 4 FILED
Feb 12, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 12, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 31, 2025 EXRA
SOU EXTENSION 3 GRANTED
Jul 30, 2025 EX3G
SOU EXTENSION 3 FILED
Jul 30, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Jul 30, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
SOU EXTENSION 2 GRANTED
Jan 24, 2025 EX2G
SOU EXTENSION 2 FILED
Jan 23, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 23, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 12, 2024 EXRA
SOU EXTENSION 1 GRANTED
Aug 12, 2024 EX1G
SOU EXTENSION 1 FILED
Aug 12, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 12, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 13, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 19, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 19, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 29, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 14, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 14, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 14, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 14, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 14, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 5, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 5, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 5, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 7, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jul 7, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jul 7, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 29, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 4, 2022 NWOS
NEW APPLICATION ENTERED
Sep 22, 2022 NWAP